AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35166029 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TA)
Number of subjects: 22
Study 33640890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydroxychloroquine therapy
Number of subjects: 100
Study 33640890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33318523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA intervention (at least 1 hour/week of supervised strenuous activity)
Number of subjects: 234
Study 33318523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary and PA interventions
Number of subjects: 234
Study 33318523 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric dietary intervention mainly based on plant-foods
Number of subjects: 234
Study 33318523 — intervention group
Group type: COMPARATOR
Intervention: General recommendations on healthy dietary and PA patterns
Number of subjects: 234
Study 616382121 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery practice (MI)
Number of subjects: 30
Study 616382121 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 34352792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental varnish containing casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) and 5% fluoride (MI varnish; GC, Japan)
Number of subjects: 80
Study 34352792 — intervention group
Group type: COMPARATOR
Intervention: Dental varnish with 5% fluoride alone (NUPRO White; Dentsply, USA)
Number of subjects: 80
Study 34352792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental varnish containing CPP‐ACP and 5% fluoride (MI varnish; GC, Japan)
Number of subjects: 80
Study 34352792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 32907559 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model involving co-location of psychologists and psychiatrists in GP practices.
Number of subjects: 24
Study 32907559 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with experienced mental health specialists.
Number of subjects: 24
Study 32907559 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model.
Number of subjects: 24
Study 35225079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training with progression from variable to fixed priority
Number of subjects: 60
Study 35225079 — intervention group
Group type: COMPARATOR
Intervention: Dual-task training with variable priority
Number of subjects: 60
Study 33039952 — intervention group
Group type: EXPERIMENTAL
Intervention: DMB (vitamin D3 1000 IU/d, magnesium 150 mg/d, vitamin B12 500 mcg/d)
Number of subjects: 43
Study 33039952 — intervention group
Group type: COMPARATOR
Intervention: Control (no DMB)
Number of subjects: 43
Study 35289741 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordinated multidisciplinary care, patient-relevant sedation plans, assessment of ventilation parameters, higher trigger for extubation readiness test, spontaneous breathing trial on low levels of respiratory support
Number of subjects: 8843
Study 35289741 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordinated multidisciplinary care
Number of subjects: 8843
Study 35289741 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8843
Study 32182889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle patterns identified as 'Discretionary consumption and TV'
Number of subjects: 710
Study 32182889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle patterns identified as 'Fruit, vegetables and outdoor'
Number of subjects: 710
Study 34446469 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma combined with standard of care
Number of subjects: 483
Study 34446469 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 483
Study 33470039 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate value of rCBVmean in long-term survivors (LTSs)
Number of subjects: 99
Study 33470039 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBVmean in short-term survivors (STS)
Number of subjects: 99
Study 32209931 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 20
Study 35033180 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of PCV at 6 weeks with a booster at 9 months (1+1 schedule)
Number of subjects: 784
Study 35033180 — intervention group
Group type: COMPARATOR
Intervention: Three primary doses of PCV at 6, 10, and 14 weeks (3+0 schedule)
Number of subjects: 784
Study 35033180 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of PCV with yellow fever vaccine at 9 months
Number of subjects: 784
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) treatment (1 g/m2)
Number of subjects: 388
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL subtypes (T cell ALL [T-ALL], B cell ALL [B-ALL] with TCF3-PBX1 or ETV6-RUNX1 fusions)
Number of subjects: 388
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL subtypes (hyperdiploid and BCR-ABL like)
Number of subjects: 388
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate pathway genes (SLC19A1, ABCC1, ABCC4, FPGS, MTHFD1)
Number of subjects: 388
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including ALL subtype, SLC19A1/(ABCC1 + ABCC4) transporter ratio, MTX infusion time, FPGS mRNA expression, and MTX systemic clearance
Number of subjects: 388
Study 33164984 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer infusion time (24 h vs. 4 h)
Number of subjects: 388
Study 34052278 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Number of subjects: 194
Study 34052278 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet (MD)
Number of subjects: 194
Study 37584752 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-lift exercise (HLE)
Number of subjects: 61
Study 37584752 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 32873926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - alternate fast days at 25% energy requirements and ad libitum feed days
Number of subjects: 46
Study 32873926 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - 75% energy requirements daily
Number of subjects: 46
Study 36166026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy (4.5 mg/kg intravenously every 3 weeks)
Number of subjects: 585
Study 36166026 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (intravenously every 3 weeks)
Number of subjects: 585
Study 36166026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy
Number of subjects: 585
Study 36166026 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 585
Study 34035414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous apical negative ultrasonic irrigation (CANUI)
Number of subjects: 120
Study 34035414 — intervention group
Group type: COMPARATOR
Intervention: Positive pressure irrigation (PPI)
Number of subjects: 120
Study 34035414 — intervention group
Group type: COMPARATOR
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 120
Study 33957881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Group A)
Number of subjects: 90
Study 33957881 — intervention group
Group type: COMPARATOR
Intervention: 2-week oral administration of S-1 (80 mg/m2/day) followed by 1 week of rest (Group B)
Number of subjects: 90
Study 33957881 — intervention group
Group type: COMPARATOR
Intervention: Group B (2-week S-1 followed by 1 week rest)
Number of subjects: 90
Study 33957881 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (alternate-day S-1)
Number of subjects: 90
Study 33957881 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (n=93)
Number of subjects: 90
Study 32007688 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDD/Fs exposure (fg TEQ/bw/day)
Number of subjects: 423
Study 32007688 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PCDD/Fs (fg TEQ/g lipid)
Number of subjects: 423
Study 32007688 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG)
Number of subjects: 423
Study 32007688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis of urinary 8-OHdG
Number of subjects: 423
Study 36501109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient formula containing B group vitamins, Bacopa monniera and Ginkgo biloba
Number of subjects: 141
Study 36501109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 36501109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient formula
Number of subjects: 141
Study 33522931 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg oral arm
Number of subjects: 48
Study 33522931 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 48
Study 35444166 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 60
Study 35444166 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 60
Study 34559992 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg per day on days 2-5)
Number of subjects: 1400
Study 34559992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 34559992 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1400
Study 32771909 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 120
Study 36272210 — intervention group
Group type: EXPERIMENTAL
Intervention: GlobalConsent (adapted web-based sexual violence prevention program)
Number of subjects: 793
Study 36272210 — intervention group
Group type: COMPARATOR
Intervention: Attention control (web-based program)
Number of subjects: 793
Study 33011836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray imaging for nasogastric tube verification
Number of subjects: 215
Study 33011836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related predictor regression model (sex, age, body mass index)
Number of subjects: 215
Study 33011836 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factor regression model (guidewire presence)
Number of subjects: 215
Study 35617329 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise
Number of subjects: 120
Study 35617329 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 120
Study 33812497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 307
Study 33812497 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or FOLFIRI)
Number of subjects: 307
Study 36163868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 250
Study 36163868 — intervention group
Group type: COMPARATOR
Intervention: Idelalisib plus rituximab or bendamustine plus rituximab (investigator's choice)
Number of subjects: 250
Study 34487977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 6
Study 34487977 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD)
Number of subjects: 6
Study 34487977 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HD)
Number of subjects: 6
Study 33932744 — intervention group
Group type: COMPARATOR
Intervention: Chain pharmacies
Number of subjects: 921
Study 33932744 — intervention group
Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 921
Study 33932744 — intervention group
Group type: COMPARATOR
Intervention: Pharmacies in Southern states
Number of subjects: 921
Study 33932744 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pharmacies
Number of subjects: 921
Study 33119613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rintatolimod treatment in the Target Subset (n = 75)
Number of subjects: 208
Study 33119613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 33401124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 60
Study 33401124 — intervention group
Group type: COMPARATOR
Intervention: Stress management training (SMT)
Number of subjects: 60
Study 35170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 204
Study 35170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 204
Study 35170124 — intervention group
Group type: COMPARATOR
Intervention: Heroin
Number of subjects: 204
Study 34115305 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated O3 (E‐O3)
Number of subjects: 8
Study 34115305 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (AA)
Number of subjects: 8
Study 32242399 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion (HPM)
Number of subjects: 36
Study 32242399 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study 33562177 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion angle of 110 degrees
Number of subjects: 16
Study 33562177 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion angles of 90, 130, and 150 degrees
Number of subjects: 16
Study 32532280 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives
Number of subjects: 300
Study 32532280 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives plus peer referral
Number of subjects: 300
Study 32532280 — intervention group
Group type: COMPARATOR
Intervention: Standard secondary distribution
Number of subjects: 300
Study 36310098 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐Medium‐Long intervals (SML‐INT; n = 7)
Number of subjects: 14
Study 36310098 — intervention group
Group type: COMPARATOR
Intervention: Long intervals (L‐INT; n = 7)
Number of subjects: 14
Study 35998966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-delivered Behavioural Activation (Do More, Feel Better; DMFB)
Number of subjects: 288
Study 35998966 — intervention group
Group type: COMPARATOR
Intervention: Clinician-delivered Behavioural Activation (BA)
Number of subjects: 288
Study 35029706 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 300 mg
Number of subjects: 33
Study 35029706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32538277 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ingredients identified in the Very Early Rehabilitation in Speech (VERSE) trial
Number of subjects: 53
Study 32538277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative intervention intensity (CII) calculated by counting identified therapeutic ingredients
Number of subjects: 53
Study 32586585 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 402
Study 32586585 — intervention group
Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 402
Study 35637624 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CBD
Number of subjects: 17
Study 35637624 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 17
Study 35637624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg CBD
Number of subjects: 17
Study 35637624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 28 mg
Number of subjects: 80
Study 34239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 80
Study 34239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 70 mg
Number of subjects: 80
Study 34239138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32051304 — intervention group
Group type: EXPERIMENTAL
Intervention: DECIDE intervention (clinical decision support system)
Number of subjects: 134
Study 32051304 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 134
Study 34798295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) administered perioperatively
Number of subjects: 82
Study 34798295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34825104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) applied in the first 10–15 min of each Physical Education class, twice a week for 16 weeks, with 14 to 20 all-out bouts intervals and a 2:1 work to rest ratio.
Number of subjects: 300
Study 34825104 — intervention group
Group type: COMPARATOR
Intervention: Usual programmed Physical Education classes (control group).
Number of subjects: 300
Study 35964210 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (30 minutes) + conventional physical therapy (30 minutes)
Number of subjects: 21
Study 35964210 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (60 minutes)
Number of subjects: 21
Study 33690826 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified audio-tactile performance technique with braille (ATPb)
Number of subjects: 90
Study 33690826 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-tactile performance technique (ATP)
Number of subjects: 90
Study 33690826 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio method (AM)
Number of subjects: 90
Study 32943843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg, then 2 mg/kg/h, IV)
Number of subjects: 90
Study 32943843 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 90
Study 34416020 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34134738 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 107
Study 34134738 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 107
Study 34970862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention groups (5 different groups) for weight maintenance for 6 months
Number of subjects: 0
Study 32818325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention adapted for SAD (MBI-SAD)
Number of subjects: 97
Study 32818325 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behaviour group therapy (CBGT)
Number of subjects: 97
Study 36306478 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention group (10 patients)
Number of subjects: 20
Study 36306478 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study 33172346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - performed the intervention programme for 18 sessions over 6 weeks
Number of subjects: 35
Study 33172346 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - continued their normal physical activities
Number of subjects: 35
Study 35469428 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 15 minutes before a high-fat high-calorie meal
Number of subjects: 36
Study 35469428 — intervention group
Group type: COMPARATOR
Intervention: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 30 minutes before a high-fat high-calorie meal
Number of subjects: 36
Study 34582369 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/d)
Number of subjects: 0
Study 34582369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34059935 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the ipsilateral hemisphere
Number of subjects: 35
Study 34059935 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) applied to the contralateral hemisphere
Number of subjects: 35
Study 32447494 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D endoscopic ear surgery (EES)
Number of subjects: 0
Study 32447494 — intervention group
Group type: COMPARATOR
Intervention: 2D endoscopic ear surgery (EES)
Number of subjects: 0
Study 35007127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle.
Number of subjects: 48
Study 35007127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 48
Study 35007127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by hematopoietic stem-cell transplantation
Number of subjects: 48
Study 34143803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nguvu intervention (8 weekly sessions delivered by lay refugee incentive workers)
Number of subjects: 311
Study 34143803 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 311
Study 35128870 — intervention group
Group type: EXPERIMENTAL
Intervention: Biao-Ben acupoints group
Number of subjects: 120
Study 35128870 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupoint group
Number of subjects: 120
Study 35128870 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 120
Study 32029252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Number of subjects: 11264
Study 32029252 — intervention group
Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 11264
Study 34057543 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (400 mg)
Number of subjects: 84
Study 34057543 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Number of subjects: 84
Study 34057543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Thiamine)
Number of subjects: 84
Study 33499921 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY), 3 times per day for 3 menstrual cycles
Number of subjects: 248
Study 33499921 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times per day for 3 menstrual cycles
Number of subjects: 248
Study 33499921 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY)
Number of subjects: 248
Study 33499921 — intervention group
Group type: COMPARATOR
Intervention: Xuefu Zhuyu (XFZY) and Placebo
Number of subjects: 248